Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome

Keyphrases

• 15N-glycine 10%
• Age-matched 10%
• AIDS/HIV 100%
• Anabolic Effect 100%
• Anabolic Response 10%
• Attenuation 10%
• Basal Metabolic Rate 10%
• Cachexia 30%
• Current Mode 10%
• Days of Treatment 10%
• GH Resistance 30%
• Growth Factors 100%
• High Dose 30%
• IGF-binding protein-3 10%
• Insulin-like 100%
• Insulin-like Growth factor-1 10%
• Lean Body Mass 10%
• Leucine 10%
• Malnutrition 10%
• Multiple Injections 10%
• Nitrogen Balance 10%
• Nitrogen Retention 30%
• Protein Accretion 10%
• Protein Turnover 10%
• Recombinant 100%
• Repeated Administration 10%
• Therapeutic Efficacy 10%
• Three-level 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Acquired Immune Deficiency Syndrome 100%
• Binding Protein 14%
• Cachexia 42%
• Carbon 13 14%
• Combination Therapy 14%
• Infection 14%
• Leucine 14%
• Nitrogen 15 14%
• Recombinant Somatomedin C 100%
• Somatomedin C 100%
• Synapsin II 14%

Biochemistry, Genetics and Molecular Biology

• Basal Metabolic Rate 10%
• Binding Protein 10%
• Drug Megadose 30%
• Insulin-Like Growth Factor 1 100%
• Lean Body Weight 10%
• Leucine 10%
• Low Drug Dose 40%
• Nitrogen Balance 10%
• Protein Degradation 10%
• Recombinant 10%
• Repeated Drug Dose 10%